Adma Biologics reported $61.59M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Omeros USD -65.12M 21.27M Jun/2024
Takeda JPY 133.86B 105.69B Dec/2025